COMMUNIQUÉS West-GlobeNewswire

-
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
07/02/2025 - 14:50 -
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
07/02/2025 - 15:15 -
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
07/02/2025 - 16:00 -
Carla da Luz Boren Recognized Among Top 50 Women Leaders in Healthcare Technology
07/02/2025 - 16:18 -
Le CMUH recommande RYBREVANT®▼ (amivantamab) par voie sous-cutanée dans le cadre du traitement des patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
07/02/2025 - 17:35 -
OHC - Ford government’s primary care announcement plays politics with people’s need for a family doctor: It’s a primary care “plan” to implement a plan delayed until the cusp of an election
07/02/2025 - 18:44 -
WAKE RADIOLOGY PROMOTES HEART HEALTH WITH ADVANCED IMAGING SERVICES AND SCREENINGS DURING FEBRUARY
07/02/2025 - 18:52 -
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
07/02/2025 - 20:56 -
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
07/02/2025 - 21:22 -
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
07/02/2025 - 22:00 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:01 -
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:01 -
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
07/02/2025 - 22:05 -
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:05 -
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:30 -
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:30 -
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:30 -
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07/02/2025 - 22:30 -
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
07/02/2025 - 22:58
Pages